Kevin Marks is a seasoned leader in the biotechnology industry, currently serving as President & CEO of Delphia Therapeutics since July 2022, where Kevin is also a co-founder. In addition, Kevin holds advisory roles at GV and has been an Entrepreneur in Residence since April 2022. Prior to joining Delphia, Kevin led oncology drug discovery efforts as Head at Novartis Institutes for BioMedical Research from September 2020 to March 2022. Kevin's extensive experience at Agios Pharmaceuticals from 2009 to 2020 includes positions such as Vice President of Biology and Sr. Director & Head of Cancer Biology, focusing on oncology and rare genetic diseases. Earlier roles included key scientific positions at Makoto Life Sciences and Curis. Kevin earned a PhD in Molecular Pharmacology/Chemical & Systems Biology from Stanford University and a BA in Biology from Cornell University.
This person is not in any teams
This person is not in any offices